Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
INTRODUCTION. Osteoporosis is a leading cause of morbidity, disability, reduced quality of life, and premature mortality in the elderly population. Denosumab is a treatment for osteoporosis; however, denosumab discontinuation may cause a rebound effect, which is a severe adverse drug reaction (ADR)...
Saved in:
| Main Authors: | N. Yu. Velts, O. V. Velts, R. N. Alyautdin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2024-07-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/435 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative efficacy of teriparatide and bisphosphonates or denosumab vs. teriparatide monotherapy in osteoporosis: a meta-analysis
by: Huan Jin, et al.
Published: (2025-05-01) -
Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future
by: Socrates E. Papapoulos, et al.
Published: (2025-07-01) -
Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment
by: Chiao-Ling Chen, et al.
Published: (2024-12-01) -
Novel injectable composite incorporating denosumab promotes bone regeneration via bone homeostasis regulation
by: Guang Yang, et al.
Published: (2024-12-01) -
Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis
by: Liangshi Chen, et al.
Published: (2025-04-01)